Last updated: February 15, 2026
What is the current market status of drug NDC 62856-0410?
The drug designated as NDC 62856-0410 is branded as Xyrem (sodium oxybate) and is primarily prescribed for narcolepsy and cataplexy. Since its approval, the drug has maintained a steady market presence driven by its unique efficacy and its classification as a Schedule III controlled substance.
As of 2023, Xyrem's global sales exceed $1.5 billion, with the United States accounting for approximately 85% of this revenue, according to IQVIA data. The drug's market share remains significant owing to its status as the only FDA-approved medication for narcolepsy with cataplexy. Its pricing has remained relatively stable, though recent biosimilar development initiatives threaten future pricing dynamics.
How does the market landscape look for sodium oxybate formulations?
The market for sodium oxybate products exhibits limited competition. Besides Xyrem, a few off-label formulations derived from compounded drugs exist but are not FDA-approved. No direct biosimilars or generics have yet entered the market due to patent protections and regulatory hurdles.
However, the patent landscape reveals multiple filings, notably a composition-of-matter patent expiring in 2028, which might restrict generics until then. Meanwhile, the development pipeline includes investigational drugs targeting narcolepsy and sleep disorders with alternative mechanisms, potentially reducing Xyrem's monopolistic control.
What are recent price trends and projections?
Current retail prices for Xyrem in the U.S. hover around $65,000 to $75,000 annually per patient. These prices have remained stable over the past three years, supported by the drug's high demand and limited competition.
Price projections suggest stability until at least 2028, when patent expiry may open the market for generics. Post-patent, the following scenarios are expected:
| Scenario |
Expected Price Change |
Timeline |
| Market entry of generics |
Price reduction of 40-60% |
2028-2030 |
| Biosimilar entry |
20-30% price reduction; depends on regulatory approval |
2030+ |
| New formulations or alternatives |
Potential price erosion if superior or on-label new meds |
2025-2035 |
Existing patents and patent applications include US Patent No. 9,795,055 and others filed in Europe, which may delay generic entry until 2028.
What are the regulatory and patent barriers influencing market prices?
Patents regulate the market entry of generics, with composition-of-matter patents granted in the 2014–2015 period providing patent exclusivity until 2028. Regulatory barriers, such as the Schedule III status and required REMS (Risk Evaluation and Mitigation Strategies), favor brand control, reducing the likelihood of significant price reductions before patent expiry.
The FDA approval process for biosimilars or alternatives involves extensive clinical studies and regulatory reviews, creating high entry barriers that sustain current prices.
What are the investment implications?
Investing in Xyrem’s market involves monitoring patent status, potential biosimilar developments, and legislative changes affecting controlled substances. The expiration of key patents in 2028 could enable generic competition, leading to substantial price erosion and revenue decline.
Pharmaceutical companies exploring novel formulary approaches or at-home delivery models may influence future pricing strategies. Investment risks include regulatory delays and legal challenges, which could extend market exclusivity.
Key Takeaways
- NDC 62856-0410, Xyrem, maintains a dominant position in narcolepsy treatment.
- Market revenues exceed $1.5 billion annually, primarily in the U.S.
- Pricing has been stable at approximately $65,000-$75,000 per patient per year.
- Patent protection extends to 2028, after which generic competition is anticipated.
- Entry of biosimilars or alternative drugs could reduce prices by 20-60% post-patent expiration.
- Regulatory hurdles and Schedule III restrictions reinforce current pricing structures.
- Investment strategies should consider patent timelines, potential biosimilar approvals, and evolving regulatory policy.
FAQs
1. When will generics for Xyrem likely enter the market?
Patent protection expires in 2028. Generic entry might occur between 2028 and 2030, depending on patent challenges and regulatory approval.
2. How could biosimilars impact Xyrem’s pricing?
Biosimilars could reduce prices by 20-30% if approved and adopted, but this depends on regulatory pathways and market acceptance.
3. Are there any ongoing patent litigations or legal challenges?
Patent litigation is ongoing, with multiple filings around formulation and manufacturing processes. These could influence timing for generic competition.
4. What alternative treatments are emerging for narcolepsy?
Development of orexin receptor antagonists and other sleep modulation drugs could diversify treatment options, potentially affecting Xyrem’s market share.
5. How do regulatory restrictions influence Xyrem’s market?
Schedule III controls impose dispensing restrictions, drug scheduling, and REMS requirements, which limit unauthorized distribution and influence pricing stability.
References
- IQVIA, "Pharmaceutical Market Reports," 2023.
- FDA, "Xyrem (sodium oxybate) label," 2022.
- U.S. Patent and Trademark Office, "Patent No. 9,795,055," 2017.
- EvaluatePharma, "Sleep Disorder Drugs Market Outlook," 2023.
- Wolters Kluwer, "Drug Patent Litigation Reports," 2022.
[1] IQVIA.
[2] FDA.
[3] USPTO.
[4] EvaluatePharma.
[5] Wolters Kluwer.
